Biodexa Pharmaceuticals annual capital expenditures (capex)
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Capital Expenditures (CapEx) Growth & History (BDRX)
Biodexa Pharmaceuticals's capital expenditures (capex) was £2,000 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £2,000 | −£7,000 | −77.78% |
| 2024 | 2024-12-31 | £9,000 | −£17,000 | −65.38% |
| 2023 | 2023-12-31 | £26,000 | −£36,000 | −58.06% |
| 2022 | 2022-12-31 | £62,000 | −£258,000 | −80.63% |
| 2021 | 2021-12-31 | £320,000 | £111,000 | +53.11% |
| 2020 | 2020-12-31 | £209,000 | −£101,000 | −32.58% |
| 2019 | 2019-12-31 | £310,000 | £66,000 | +27.05% |
| 2018 | 2018-12-31 | £244,000 | −£463,000 | −65.49% |
| 2017 | 2017-12-31 | £707,000 | −£640,000 | −47.51% |
| 2016 | 2016-12-31 | £1.3M | £425,000 | +46.10% |
| 2015 | 2015-12-31 | £922,000 | — | — |
Biodexa Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Biodexa Pharmaceuticals's capital expenditures (capex) decreased from £209,000 to £2,000, a change of −£207,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...